Abselion
Simon Douglas is a seasoned leader in the biotechnology and healthcare sectors, currently serving as Non Executive Chairman at Abselion since November 2021 and Fusion Antibodies plc since 2006. With a background in developing innovative laboratory instruments at Abselion and spearheading antibody discovery services at Fusion Antibodies, Douglas also holds the position of Chief Executive at C Major Medical, specializing in patented auto-retracting needle technology. Previous roles include Non Executive Chairman at Cambridge Nutritional Sciences, Chief Executive at Biofortuna, and various leadership roles at Lab 901, Invitrogen, and DRI. Douglas earned an MPhil and PhD in Antibody Imaging of Tumours, along with a BSc in Chemistry from the University of Southampton.
This person is not in any teams
This person is not in any offices
Abselion
Our mission at Abselion is to unlock the secrets of proteins and their interactions. We want to create the tools that enable anyone to understand how a protein behaves, what its properties are and how it interacts with other molecules, e.g. analysis of binding interactions for QC. Our tools help researchers to develop the medicine of the future, to find the best ways to produce novel biomolecules and to assure that medicine is always safe and efficacious. Our focus lies on convenient tools with high degree of automation and low hands-on time. We are a dynamic, interdisciplinary team working at the intersection of biology, nanotechnology and data science. We value a flat hierarchy, where everyone is encouraged to share their ideas and to follow their passion. We believe it is important to move fast, to make mistakes and then to try again.